There is no difference between proton radiotherapy and intensity-modulated radiotherapy when comparing the toxicity among Medicare beneficiary patients with prostate cancer at 12 months post-treatment, according to a new study.
There is no difference between proton radiotherapy and intensity-modulated radiotherapy when comparing the toxicity among Medicare beneficiary patients with prostate cancer at 12 months post-treatment, according to a new study.